日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study

KEYNOTE-564 III期研究东亚亚组中肾细胞癌辅助治疗帕博利珠单抗与安慰剂的比较

期刊:Cancer Research and Treatment
影响因子:3.8
doi:10.4143/crt.2025.365
Park, Se Hoon; Chang, Yen-Hwa; Lee, Jae Lyun; Choueiri, Toni K; Kimura, Go; Chung, Jinsoo; Masumori, Naoya; Nishimura, Kazuo; Kato, Minoru; Kato, Haruaki; Numakura, Kazuyuki; Chang, Chao-Hsiang; Anai, Satoshi; Tsunemori, Hiroyuki; Chen, Chung-Hsin; Lin, Jianxin; Elfiky, Aymen; Burgents, Joseph E; Kitamura, Hiroshi
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2026
文献求助 收藏

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

来自 III 期随机 CLEAR 试验的生物标志物分析：乐伐替尼联合帕博利珠单抗对比舒尼替尼治疗晚期肾细胞癌

期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2024.12.003
Motzer, R J; Porta, C; Eto, M; Hutson, T E; Rha, S Y; Merchan, J R; Winquist, E; Gurney, H; Grünwald, V; George, S; Markensohn, J; Burgents, J E; Cristescu, R; Sachdev, P; Narita, Y; Huang, J; Zhao, Z; Okpara, C E; Minoshima, Y; Choueiri, T K
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2025
文献求助 收藏

Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

帕博利珠单抗联合阿昔替尼对比舒尼替尼治疗晚期透明细胞肾细胞癌：KEYNOTE-426 III期试验的5年生存率和生物标志物分析

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-03867-5
Rini, Brian I; Plimack, Elizabeth R; Stus, Viktor; Gafanov, Rustem; Waddell, Tom; Nosov, Dmitry; Pouliot, Frédéric; Alekseev, Boris; Soulières, Denis; Melichar, Bohuslav; Vynnychenko, Ihor; de Azevedo, Sergio Jobim; Borchiellini, Delphine; McDermott, Raymond S; Bedke, Jens; Tamada, Satoshi; Wu, Sterling; Markensohn, Julia; Zhang, Yiwei; Loboda, Andrey; Vajdi, Amir; Perini, Rodolfo F; Burgents, Joseph; Powles, Thomas
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2025
文献求助 收藏

Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

CLEAR试验的事后分析：接受乐伐替尼联合帕博利珠单抗治疗的肾细胞癌患者与接受舒尼替尼治疗的肾细胞癌患者按基线转移情况划分的临床结局

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.35288
Grünwald, Viktor; McKay, Rana R; Buchler, Tomas; Eto, Masatoshi; Park, Se Hoon; Takagi, Toshio; Zanetta, Sylvie; Keizman, Daniel; Suárez, Cristina; Négrier, Sylvie; Lee, Jae Lyun; Santini, Daniele; Bedke, Jens; Staehler, Michael; Kollmannsberger, Christian; Choueiri, Toni K; Motzer, Robert J; Burgents, Joseph E; Xie, Ran; Okpara, Chinyere E; Powles, Thomas
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2025
文献求助 收藏

Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

在 CLEAR 3 期研究的最终预设生存分析中，对晚期肾细胞癌患者接受乐伐替尼联合帕博利珠单抗治疗的反应进行特征分析

期刊:
影响因子:
doi:10.1016/j.eururo.2024.03.015
Motzer, Robert J; Choueiri, Toni K; Hutson, Thomas; Young Rha, Sun; Puente, Javier; Lalani, Aly-Khan A; Winquist, Eric; Eto, Masatoshi; Basappa, Naveen S; Tannir, Nizar M; Vaishampayan, Ulka; Bjarnason, Georg A; Oudard, Stéphane; Grünwald, Viktor; Burgents, Joseph; Xie, Ran; McKenzie, Jodi; Powles, Thomas
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

美国转移性去势抵抗性前列腺癌患者在PARP抑制剂应用前的真实世界治疗模式和总体生存率

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-021-01823-6
Shore, Neal D; Laliberté, François; Ionescu-Ittu, Raluca; Yang, Lingfeng; Mahendran, Malena; Lejeune, Dominique; Yu, Louise H; Burgents, Joseph; Duh, Mei Sheng; Ghate, Sameer R
PARP
肿瘤
前列腺癌
肿瘤免疫
发表日期：2021
文献求助 收藏

Migratory properties of pulmonary dendritic cells are determined by their developmental lineage

肺树突状细胞的迁移特性取决于其发育谱系。

期刊:Mucosal Immunology
影响因子:7.6
doi:10.1038/mi.2012.106
Nakano, H; Burgents, J E; Nakano, K; Whitehead, G S; Cheong, C; Bortner, C D; Cook, D N
发育与干细胞
树突状细胞
细胞生物学
树突状细胞
免疫/内分泌
发表日期：2013
文献求助 收藏

The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells

炎症小体组分NLRP3通过增强肿瘤相关髓源性抑制细胞的积累来削弱抗肿瘤疫苗的作用。

期刊:Cancer Research
影响因子:16.6
doi:10.1158/0008-5472.CAN-10-1921
van Deventer, Hendrik W; Burgents, Joseph E; Wu, Qing Ping; Woodford, Rita-Marie T; Brickey, W June; Allen, Irving C; McElvania-Tekippe, Erin; Serody, Jonathan S; Ting, Jenny P-Y
肿瘤
炎症
炎性小体
肿瘤免疫
炎症/感染
LRP3
NLRP3
细胞生物学
炎性小体
免疫/内分泌
发表日期：2010
文献求助 收藏

L-selectin is dispensable for T regulatory cell function postallogeneic bone marrow transplantation

同种异体骨髓移植后，L-选择素对T调节细胞功能并非必需。

期刊:American Journal of Transplantation
影响因子:8.2
doi:10.1111/j.1600-6143.2010.03319.x
Carlson, M J; Fulton, L M; Coghill, J M; West, M L; Burgents, J E; Wan, Y; Panoskaltsis-Mortari, A; Tedder, T F; Blazar, B R; Serody, J S
细胞生物学
发表日期：2010
文献求助 收藏